News & Trends - Pharmaceuticals

MSD, Novartis and more unite alongside Gates Foundation in the flight against COVID-19

Health Industry Hub | March 30, 2020 |
[Total: 1    Average: 5/5]

Pharma News: A consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic.

The industry brings a range of assets, resources, and expertise needed to identify effective and scalable solutions to the pandemic that is affecting billions worldwide. Effects on health systems, economies, and livelihoods are significant, and effective response requires an unprecedented collaboration across government, academia, private sector, and philanthropy.

As co-chair of a consortium of life science companies headquartered across three continents, Vas Narasimhan, CEO of Novartis, said, “We feel a deep shared responsibility to see if there are specific areas where collaboration across the life sciences industry and the Bill & Melinda Gates Foundation can accelerate solutions to this pandemic. In addition to the individual contributions companies are already making, collective action is critical to ensure any promising studies into vaccines, drugs, and diagnostics are quickly scaled to people around the world who are affected by this pandemic.”

HCP engagement during COVID-19. Fill the gap of reduced fieldforce activities. Health Industry Hub combines expertise in delivering digital health content and measuring engagement with 20+ years industry experience. Created by industry for industry. Contact us.

Companies participating in the collaboration include GSK, Pfizer, MSD, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Gilead, Johnson & Johnson, Merck KGaA, Novartis, Sanofi, BD and bioMérieux.

Trials of existing drugs, diagnostic tests, compounds, and investigational vaccines have begun around the world to identify interventions to slow or end the pandemic. Products that demonstrate efficacy will require clinical study, scale up of manufacturing, and distribution if proven effective. These are areas that the life sciences industry has extensive experience in managing for products that reach billions of people every day.

Mark Suzman, chief executive officer of the Bill & Melinda Gates Foundation said, “We know that the private sector is where the technical skills from discovery to clinical trials to commercialization know-how sits. We look to harness that knowledge and experience, combine it where possible, to connect with national regulators and the World Health Organization to see if we can help flatten the curve of this pandemic and make sure the results reach everyone around the world, particularly those at highest risk and the poorest.”

Following a conference call with Gates Foundation leadership earlier this month, companies are working to identify concrete actions that will accelerate treatments, vaccines, and diagnostics to the field. As a first step, 15 companies have agreed to share their proprietary libraries of molecular compounds that already have some degree of safety and activity data – with the COVID-19 Therapeutics Accelerator launched by the Gates Foundation, Wellcome, and Mastercard two weeks ago to quickly screen them for potential against COVID-19. Successful hits would move rapidly into in vivo trials in as little as two months.

“This is an encouraging start in a critical area because if any of these compounds are shown to be effective against COVID-19 it dramatically accelerates the path to product approval and scale up,” said Suzman. “While each of the partners will also be pursuing other efforts in partnership with national governments and other partners, it is a great example of why we are optimistic that this unprecedented collaboration will provide a platform for a fundamentally different kind of partnership to help address this global health emergency.”

Register FREE and join 20,000+ industry professionals who receive the latest industry news, innovations and insights from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Pharmaceuticals

Pharma News - 20 biopharmaceutical companies enter a ground-breaking partnership - AMR Action Fund

20 biopharmaceutical companies enter a ground-breaking partnership

Health Industry Hub | July 10, 2020 |

Please log in to Health Industry Hub to view this content in the ‘News & Trends’ menu.

Health Industry Hub is Australia’s ONLY one-stop-hub connecting Pharma, Biotech and MedTech industry professionals. Learn more.

More


Market Research & Insights

Market Research Pharma Biotech MedTech - Incredible breadth of Australia’s COVID-19 research: From vaccines to aircon filters

Incredible breadth of Australia’s COVID-19 research: From vaccines to aircon filters

Health Industry Hub | July 9, 2020 |

Market Research & Insights: Since the coronavirus hit Australia’s shores, health and medical researchers have been rapidly redeployed in unprecedented […]

More


Mentoring

Pharma Biotech Medtech Mentoring - Award-winning IMNIS program fosters collaboration and innovation between industry and academia

Award-winning IMNIS program fosters collaboration and innovation between industry and academia

Health Industry Hub | July 9, 2020 |

Mentoring: The Industry Mentoring Network in STEM (IMNIS) provides PhD student mentees an understanding of the industry sector, strengthen their […]

More


Communication

Communication Public Relations Pharma Biotech Medtech - The changing landscape of Pharma corporate communications - interview

The changing landscape of corporate communications in the Pharma industry

Health Industry Hub | July 8, 2020 |

COVID-19 has had a dramatic impact on the role and nature of healthcare communications, especially following the recent bushfire crisis […]

More